Choroidal Neovascular Membrane Association with Tumoral Calcinosi, a Case Report

Karim M Talaat*, Khalid H Allam1, Lujain T Idrees1 and Zahid Altaf2

1Department of Ophthalmology, National Guard Hospital, Saudi Arabia
2Department of Radiology, National Guard Hospital, Saudi Arabia

*Corresponding author: Karim Mohamed Talaat, Senior Consultant, Departments of Ophthalmology, Section Head, National Guard Hospital, PO Box 9515, Postal Code 21423, Jeddah, Saudi Arabia, Tel: +966-12-226-6666; Email: ktalaat11@hotmail.com

Submission: January 13, 2018; Published: February 20, 2018

Abstract
To report a case of choroidal neovascular membrane in a tumoral calcinosi patient, 2 eyes from 1 patient with choroidal neovascular membrane in one eye, a 40-year-old male with a history of Tumoral calcinosi presented with a choroidal neovascular membrane in his right eye, with his medical work up consisting of elevated levels of phosphorus and normal levels of calcium, with radiological imaging consistent with the diagnosis of tumoral calcinosi. We describe a case of choroidal neovascular membrane in tumoral calcinosi, and its response to Intravitreal anti-VEGF injections.

Keywords: Choroidal Neovascular Membrane; Intravitreal Injections; Tumoral Calcinosi

Case Report
A 40-year-old male with a history of Tumoral calcinosi presented in our clinic on November 2011 complaining of decreased visual acuity in his right eye for the past 2 weeks. His past medical history included arthritis in his large joints primarily his knees, iron deficiency anaemia and hyperphosphatemia. He was on multiple medications including: Cholecalciferol, Ferrous Sulphate, Folic Acid, Omeprazole and Multivitamins. His past surgical history was unremarkable.

On presentation to our ophthalmic service his visual acuity was 6/21 OD and 6/6 OS. Intraocular pressures were 13 mmhg OD and 12 mmhg OS by Tono-pen measurements. Slit Lamp examination revealed perilimbal Calcification OU nasally otherwise a normal anterior segment examination bilaterally. Fundus examination showed myelinated nerve fibers, punched out chorioretinal lesions in the periphery, angiod streaks and subretinal haemorrhage at the macula with a central retinal thickness of 329 microns with subretinal fluids. Flourescein angiogram confirmed presence of subfoveal choroidal neovascular membrane OD.

Patient received Ranibizumab (Lucentis, Novartis Pharm. Lim, Horsham, West Sussex, UK) intravitreal injection 6th of December 2011, 18 days post intravitreal injection, BCVA right eye 6/24 and OCT shows less subretinal fluid compared to first visit, in December 26 the thickness was 290 microns. Patient had his second Lucentis injection on 3rd January 2012. On 24th January 2012 (3 weeks post injection) BCVA right eye 6/21, and OCT showed even less subretinal fluid than what was previously noted.

Third Lucentis Injection was given on 31st of January 2012, 3 weeks later the patient was followed up with a BCVA right eye 6/24 with almost no sub retinal fluid. On 20th of March 2012 BCVA right eye 6/60 with no sub retinal fluid. On 17th of April 2012 BCVA of the right eye 6/36 with a central retinal thickness of 276 microns with no sub retinal fluid.

On 16th of May 2012 BCVA right eye is 6/36 OCT shows a small pocket of sub retinal fluid in which we decide to inject Lucentis 4th time which was performed on 29th of May 2012 to regain some of the lost visual acuity. Patient was then seen on 11th of June and the BCVA 6/36 and the sub retinal fluid resolved. On 25th of July OCT showed Mild SRF under the fovea. Patient disappeared and showed up 23rd October 2012, with BCVA right eye 6/18-2, and OCT right eye showing a dry macula. On 28 January 2013 BCVA 6/18 OCT Dry Macula. On 13th of March 2013, BCVA 6/60, OCT Macula dry, we thought decrease visual acuity could be due to RPE atrophy, trial of Lucentis advised, which was performed 19th of March 2013.

One-month post injection VA didn’t improve and OCT still dry. 3 months later on 24th of July 2013, BCVA 6/30 and left eye 6/6 patient was complaining of Visual Field disturbance in his left eye. OCT left eye shows no sub retinal fluid dry macula which was confirmed with FFA showing NO CNV in left eye. On his last visit on 11/8/2015 his vision was CF right eye with no sub retinal fluid in OCT and 6/6 left eye with no changes in OCT.

Discussion
Tumoral calcinosi is a subtype of a group of disorders classified under calcinosi cutis. Calcinosi cutis is classified into four types
being metastatic. Dystrophic, Intraepidermal calcified nodules and idiopathic type [1], it affects a certain age group of adolescents to young adults [2] with special association and expressibility in afro-Caribbean descent in particular [3]. The Term Tumoral calcinosis was first described in literature in 1943 [4] with certain characteristics as such of elevation of serum phosphate levels, elevated renal tubular phosphate reabsorption and / or normal or elevated serum 1,25-dihydroxyvitamin D [5]. It is characterized with considerable subcutaneous deposits of calcium phosphate near joints of upper and lower limbs such as elbows, hands wrists, hips, knees and feet with these deposits consisting mainly of pleomorphic calcium phosphate crystals. Keeping in mind that calcium and parathyroid hormone levels being on a normal level basis.

It has been linked with certain ophthalmic presentations that are associated with calcification such as calcific lid lesions of the eyelid, Band keratopathy, Conjunctival calcific lesions, angioid streaks and choroidal neovascular membranes [6-14]. To our knowledge this is the Third published case in the English literature that describes the involvement of Tumoral Calcinosis with choroidal neovascular membrane in the retina.

Perimbal calcification was present but no eyelid calcifications which have been mentioned in previous studies [12, 13], Radiologic imaging revealed multi lobulated amorphous, cloud-like calcification located in a periarticular distribution adjacent to the right knee, inferior to the right shoulder and around the left hip joint. No significant secondary bone changes.

Recent report in treatment of CNV secondary to angioid streaks in cases of tumoral calcinosis shows great improvement post anti-VEGF injection to affected eyes with CNV after a trial of 3 Lucentis injections and follow up over 6 months [12], however in our particular patient the visual acuity fluctuated in response to Anti-VEGF injections. Follow up period in total was 46 months, which was longer than the previous 2 studies that mentioned the association of CNVM in tumoral calcinosis patients.

With the small number of reports found in relation of tumoral calcinosis associated with CNV it is difficult to establish a clear treatment algorithm, further studies and investigations are needed and patients with tumoral calcinosis are advised to visit the ophthalmic clinic if they complain of changes in vision in order to gain proper management.

Acknowledgments

We would like to thank Richard Florentino for his aid.

References